






# Imipenem + cilastatin

NOT RECOMMENDED AS AN  
ESSENTIAL MEDICINE

Section: [6. Anti-infective medicines](#) > [6.2. Antibacterials](#) > [6.2.2. Watch group antibiotics](#)

		EMLc	ATC codes: <a href="#">J01DH51</a>
Indication	Pseudomonas aeruginosa resistant to other antibiotic	ICD11 code: <a href="#">MG50.8Y</a>	
INN	Imipenem + cilastatin		
Medicine type	Chemical agent		
Antibiotic groups	 WATCH		
List type	Complementary (EML) (EMLc)		
Formulations	Parenteral > General injections > IV: 250 mg (as monohydrate) + 250 mg (as sodium salt) powder for injection ; 500 mg (as monohydrate) + 500 mg (as sodium salt) powder for injection		
EML status history	First added in 1997 ( <a href="#">TRS 882</a> ) Changed in 2002 ( <a href="#">TRS 914</a> ) Changed in 2007 ( <a href="#">TRS 950</a> ) Changed in 2009 ( <a href="#">TRS 958</a> ) Removed in 2017 ( <a href="#">TRS 1006</a> )		
Sex	All		
Age	Also recommended for children		
Therapeutic alternatives	The recommendation is for this specific medicine		
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 		
Wikipedia	<a href="#">Imipenem + cilastatin</a> 		
DrugBank	<a href="#">Imipenem</a>  <a href="#">Cilastatin</a> 		

## Summary of evidence and Expert Committee recommendations

As part of the syndrome-based comprehensive review of antibacterials on the Model Lists, imipenem + cilastatin was removed from the EML and EMLc. However, it is acknowledged in the lists as an alternative to meropenem except for acute bacterial meningitis where meropenem is preferred.

